

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/810,517
				Filing Date	March 26, 2004
				First Named Inventor	Kreft et al.
				Group Art Unit	1626
				Examiner Name	unassigned
Sheet	2	of	6	Attorney Docket Number	AM-101251

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
GS	AI	US-5,571,821	Chan, et al.	11-05-1996	
	AJ	US-5,464,853	Chan, et al.	01-07-1997	
	AK	US-5,591,761	Chan, et al.	05-07-1996	
	BA	US-5,514,691	Chan, et al.	11-07-1995	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)				
GS	BL	EP-652,009	05-10-1995	V. John		
	BM	EP-510,700-A2	10-28-1992	K. Itoh et al.		
	BN	EP-1,172,361-A1	12-14-1999	Watanabe et al.		
	BO	JP-5-148233	06-15-1993	Y. Ito		√
	BP	JP-11-343279	01-16-2002	F. Watanabe		
	BQ	WO-01/27091-A1	04-19-2001	Thompson		
	CL	WO-01/27108-A1	04-19-2001	Thompson		
	CM	WO-01/23379-A1	04-05-2001	Arkinstall et al.		
	CN	EP-1,088,821-A1	04-04-2001	Arkinstall		

Examiner Signature	/Golam Shameem/ (09/14/2006)	Date Considered	09/14/2006
--------------------	------------------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/810,517
				Filing Date	March 26, 2004
				First Named Inventor	Kreft et al.
				Group Art Unit	1626
				Examiner Name	unassigned
Sheet	3	of	6	Attorney Docket Number	AM-101251

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
GS	BB	US-6,657,070	12-02-2003	Resnick, et al.	
	BC	US-6,610,734	08-26-2003	Kreft, et al.	
	BD	US-20030229127-A1	12-11-2003	Kreft, et al.	
	BE	US-20030144531-A1	07-31-2003	Kreft, et al.	
	BF	US-20040006050-A1	01-08-2004	Kreft, et al.	
	BG	6,566,536	05-20-2003	Muller, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)				
GS	CO	WO-01/70677-A1	09-27-2001	Belanger et al.		
	CP	WO-02/057252-A1	07-25-2002	Kreft et al.		
	CQ	WO-03/050063-A1	06-19-2003	Kreft et al.		
	DL	WO-03/103660-A1	12-18-2003	Kreft et al.		
	DM	WO-03/050062-A1	06-19-2003	Resnick et al.		

Examiner Signature	/Golam Shameem/ (09/14/2006)	Date Considered	09/14/2006
--------------------	------------------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/810,517
				Filing Date	March 26, 2004
				First Named Inventor	Kreft et al.
				Group Art Unit	1626
				Examiner Name	unassigned
Sheet	4	of	6	Attorney Docket Number	AM-101251

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
GS	AR	A. LARNER et al, "Review - Central & Peripheral Nervous Systems - Alzheimer's Disease: Towards Therapeutic Manipulation of the Amyloid Precursor Protein and Amyloid β -peptides", Exp. Opin. Ther. Patents, 7(10):1115-1127 (1997)	
	AS	C. MOORE et al, "Inhibition of β -amyloid Formation as a Therapeutic Strategy", Exp. Opin. Ther. Patents, 9(2):135-146 (1999)	
	AT	V. JOHN et al, "Alzheimer's Disease: Recent Advances on the Amyloid Hypothesis", in Annual Reports in Medicinal Chemistry, Chapter 2, pp. 11-20 (1997)	
	AU	G. RISHTON et al, "Fenchylamine Sulfonamide Inhibitors of Amyloid β Peptide Production by the γ -Secretase Proteolytic Pathway: Potential Small-Molecule Therapeutic Agents for the Treatment of Alzheimer's Disease", J. Med. Chem., 43(12):2297-2299 (June 15, 2000)	
	AV	B. TESTA et al, "Prodrugs Revisited: The "Ad Hoc" Approach as a Complement to Ligand Design", Medicinal Research Reviews, 16(3):233-241 (May, 1996)	
	AW	D. SKOVRONSKY et al, " β -Secretase Revealed: Starting Gate for Race to Novel Therapies for Alzheimer's Disease", TIPS, 21:161-163 (May, 2000)	
	AX	A. GHOSH et al, "Design of Potent Inhibitors for Human Brain Memapsin 2 (β -Secretase)", J. Am. Chem. Soc., 122:3522-3523 (2000)	
	AY	W. ESLER et al, "Transition-State Analogue Inhibitors of γ -Secretase Bind Directly to Presenilin-1", Nature Cell Biology, 2:428-434 (July, 2000)	
	AZ	Y-M. LI et al, "Photoactivated γ -Secretase Inhibitors Directed to the Active Site Covalently Label Presenilin 1", Nature, 405:689-694 (June, 2000)	
V	BR	M. WOLFE et al, "A Substrate-Based Difluoro Ketone Selectively Inhibits Alzheimer's β -Secretase Activity", J. Med. Chem., 41:6-9 (January 1, 1998)	

Examiner Signature	/Golam Shameem/ (09/14/2006)	Date Considered	09/14/2006
--------------------	------------------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/810,517
				Filing Date	March 26, 2004
				First Named Inventor	Kreft et al.
				Group Art Unit	1626
				Examiner Name	unassigned
Sheet	5	of	6	Attorney Docket Number	AM-101251

NONPATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
GS	BS	S. SINHA et al, "Purification and Cloning of Amyloid Precursor Protein β -Secretase from Human Brain", Nature, 402:537-540 (December, 1999)		
	BT	A. GOATE, "Monogenetic Determinants of Alzheimer's Disease: APP Mutations", CMLS Cell. Mol. Life Sci., 54:897-901 (September, 1998)		
	BU	M. SABBAGH et al, " β -Amyloid and Treatment Opportunities for Alzheimer's Disease", Alzheimer's Disease Review, 3:1-19 (1997)		
	BV	C. AUGELLI-SZAFRAN et al, " β -Amyloid as a Target for Alzheimer's Disease Therapy, in Annual Reports in Medicinal Chemistry, Chapter 3, pp. 21-30 (1999)		
	BW	J-C. DODART et al, "The β -Amyloid Precursor Protein and its Derivatives: from Biology to Learning and Memory Processes", Reviews in the Neurosciences, 11(2-3):75-93 (2000)		
	BX	D. SMALL et al, "Alzheimer's Disease and the Amyloid β Protein: What is the Role of Amyloid?", Journal of Neurochemistry, 73(2):443-449 (August, 1999)		
	BY	J. NASLUND et al, "Correlation Between Elevated Levels of Amyloid β -Peptide in the Brain and Cognitive Decline", JAMA, 283(12):1571-1577 (March, 2000)		
	BZ	Q-X. LI et al, "The Amyloid Precursor Protein of Alzheimer Disease in Human Brain and Blood", Journal of Leukocyte Biology, 66:567-574 (October, 1999)		
	CR	S. WAGNER et al, "Modulation of Amyloid β Protein Precursor Processing as a Means of Retarding Progression of Alzheimer's Disease", The Journal of Clinical Investigation, 104(10):1329-1332 (November, 1999)		
	CS	Y. HAN et al, "Total Asymmetric Synthesis of Highly Constrained Amino Acids Isopropyl-2', 6'-Dimethyl-Tyrosines", Tetrahedron Letters, 38(29):5135-5138 (1997)		
✓	CT	M. FINDEIS et al, "Modified-Peptide Inhibitors of Amyloid β -Peptide Polymerization", Biochemistry, 38(21):6791-6800 (May, 1999)		

Examiner Signature	/Golam Shameem/ (09/14/2006)	Date Considered	09/14/2006
-----------------------	------------------------------	--------------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 6

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	10/810,517
Filing Date	March 26, 2004
First Named Inventor	Kreft et al.
Group Art Unit	1626
Examiner Name	unassigned
Attorney Docket Number	AM-101251

NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
GS	CU	ROGGO, "Inhibition of BACE, A Promising Approach to Alzheimer's Disease Therapy", Curr. Top. Med. Chem., 2(4): 359-70 (April 2002)	
	CV	TUNG et al., "Design of Substrate-Based Inhibitors of Human β -Secretase", J. Med. Chem., 45(2):259-262 (2002)	
	CW	JOSIEN, "Recent Advances in the Development of Gamma-Secretase Inhibitors", Curr. Opin. Drug. Discov. Devel., 5(4):513-25 (July 2002)	
	CX	DOVEY et al., "Functional Gamma-Secretase Inhibitors Reduce Beta-Amyloid Peptide Levels in Brain", J. Neurochem., 76:173-181 (January 2001)	
	CY	OLSON et al., "Chapter 4. Secretase Inhibitors as Therapeutics for Alzheimer's Disease", Ann. Reports in Med. Chem., 35:31 (2000)	
	CZ	VARGHESE et al., "Chapter 2. Alzheimer's Disease: Recent Advances on the Amyloid Hypothesis", Ann. Reports Med. Chem., 32:11 (1997)	
	DL	Abstract of Japanese Patent No. JP-11-343279, January 26, 2002	

Examiner Signature	/Golam Shameem/ (09/14/2006)	Date Considered	09/14/2006
--------------------	------------------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known		
	Application Number		
	10/810,517		
	Filing Date		
	March 26, 2004		
	First Named Inventor		
Kreft et al.			
Art Unit			
1626			
Examiner Name			
unassigned 1626			
Attorney Docket Number			
AM-101251			

Sheet	1	of	1
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
GS	DM	WERMUTH et al., "Molecular variations based on isosteric replacements", Prac. Med. Chem., Academic Press, pp. 203-237 (February 1996)	

Examiner Signature	/Golam Shameem/ (09/14/2006)	Date Considered	09/14/2006
-----------------------	------------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.